<DOC>
	<DOCNO>NCT01214486</DOCNO>
	<brief_summary>The primary purpose study analyze compare plasma intracellular concentration Raltegravir ( RAL ) blood plasma peripheral blood mononuclear cell , use high performance liquid chromatography ( HPLC ) .</brief_summary>
	<brief_title>Measurement Plasma Intracellular Concentrations Raltegravir</brief_title>
	<detailed_description>Integrase strand transfer inhibitor one new class antiretroviral drug . This class drug inhibit catalytic activity HIV-1 integrase , HIV-1-encoded enzyme require viral replication [ 1 ] . Inhibition integrase prevents covalent insertion unintegrated , linear HIV-1 DNA host cell genome , therefore prevent formation HIV-1 provirus . RAL , first agent class , initially approve 2007 use patient harbor drug-resistant HIV [ 2 ] . More recently , FDA expand indication RAL use HIV-infected patient antiretroviral naïve [ 3 ] . The currently approve dose 400 mg twice daily . The RAL area-under-the-curve ( AUC ) Cmax increase dose-dependent fashion range 100 mg 1,600 mg. With twice-daily dosing , PK steady state achieve within approximately first 2 day . Considerable variability observe PK raltegravir clinical trial . In clinical trial participant receive twice-daily RAL 400 mg , drug exposure characterize geometric mean AUC within first 12 hour 14.3 mcM ( hr ) plasma concentration 12 hour 142 nM [ 3 ] . RAL concentration 6 50 nM result 95 % inhibition ( EC95 ) viral spread mitogen-activated human peripheral blood mononuclear cell ( PBMCs ) infect diverse , primary clinical isolates HIV-1 , include isolates resistant reverse transcriptase inhibitor protease inhibitor ( PIs ) . The absolute bioavailability RAL establish . RAL approximately 83 % bound human plasma protein concentration range 2 10 mcM . The apparent terminal half-life RAL approximately 9 hour , short alpha-phase half-life ( 1 hour ) , account much AUC . Determination drug level guide treatment HIV infection available protease inhibitor ( PI ) non-nucleoside reverse transcriptase inhibitor ( NNRTI ) yet consider standard care [ 4,5 ] . RAL associate potent performance HIV treatment-naïve patient limited treatment option , potentially bind interaction HIV preintegration complex . When RAL bind complex , drug dissociates rate slow half-life complex , make bind essentially irreversible . Thus , efficacy RAL may dependent intracellular binding level drug preintegration complex , rather plasma concentration RAL . Because , postulate intracellular concentration RAL likely correlate biological activity HIV . Moreover , pharmacokinetic behavior predict , depend trough concentration observe , drug might suitable different dose approach include day administration . This would create flexibility patient , chance improve adherence .</detailed_description>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Be age great equal 19 year Have document HIV Be take RAL least 7 day Any acute intercurrent illness might interfere interpretation study</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>HIV</keyword>
	<keyword>RAL</keyword>
	<keyword>Raltegravir</keyword>
	<keyword>Isentress</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>